Glomerulonephritis

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
3 Unique sponsors
3 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
L Oncology (ATC L) 2
H Endocrinology (ATC H) 1
Mechanism of action (INN-stem analysis)
Monoclonal antibody (human) 1 substance
Monoclonal antibody (chimeric) 1 substance
Unknown / small molecule 1 substance
Phase III: 1 Phase II/III: 2 Phase I: 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • Medical University Of Bialystok Academic
    DESMOPRESSIN ACETATE
    2024-516270-30-00 1 country 2022 n=454
    Ended

Phase II/III

2 trials
  • Academisch Ziekenhuis Leiden Academic
    BELIMUMAB; RITUXIMAB
    2023-507867-20-00 1 country 2018 n=30
    Recruiting
  • Academisch Ziekenhuis Leiden Academic
    BELIMUMAB; RITUXIMAB
    2023-507867-20-00 1 country 2018 n=30
    Recruiting

Phase I

1 trial
  • Walden Biosciences Inc. Commercial
    IMP not specified
    2024-516446-18-00 1 country n=84
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Academisch Ziekenhuis Leiden Academic 2 Phase II/III 2
Walden Biosciences Inc. Commercial 1 Phase I 0
Medical University Of Bialystok Academic 1 Phase III 0
New trials by year
2022
1
← All indication landscapes